IFNAR2 (Interferon alpha/beta receptor 2) variants and mutations
IFNAR2 (also known as Interferon alpha/beta receptor 2) is a human protein-coding gene encoding an interferon alpha/beta receptor 2 protein. It provides the high-affinity ligand-binding component of the type I interferon receptor complex and triggers antiviral JAK-STAT signaling with IFNAR1. Biallelic loss-of-function variants can predispose to severe viral infections, including critical COVID-19 in some individuals. This analysis covers 720 IFNAR2 variants and mutations. Of these, 77% have computational variant effect predictions. Disease context includes immunodeficiency 45, COVID-19, and chronic hepatitis B virus infection. Example IFNAR2 variants include L2I, L2F, and L2V.
Variant analysis overview
- Gene: IFNAR2
- Protein: Interferon alpha/beta receptor 2
- UniProt accession: P48551
- Organism: Homo sapiens
- Variants analyzed: 720
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 598 unspecified-consequence records; 63 missense variants; 40 synonymous variants; 9 frameshift variants; 6 stop-gained variants; 4 in-frame deletions; 2 splice-region variants
- Prediction scores: 553 variants have prediction scores (77% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: immunodeficiency 45, COVID-19, chronic hepatitis B virus infection, chronic hepatitis C virus infection, multiple sclerosis, neoplasm, hepatitis C virus infection, melanoma, hepatitis B virus infection, acquired polycythemia vera, essential thrombocythemia, hairy cell leukemia.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 9 post-translational modification sites.
- Structural context: 20 variants have structural context.
- PTM context: 15 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable IFNAR2 variants
Examples include L2I, L2F, L2V, L2L, L3S, p.Leu3del, S4G, S4P. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- L2I (p.Leu2Ile), gnomAD 21-33241926-C-A, REVEL 0.05, CADD 7.22
- L2F (p.Leu2Phe), gnomAD 21-33241926-C-T, REVEL 0.04, CADD 8.36
- L2V (p.Leu2Val), gnomAD 21-33241926-C-G, REVEL 0.02, CADD 5.36
- L2L (p.Leu2Leu), gnomAD 21-33241928-T-A, CADD 6.68
- L3S (p.Leu3Ser), ESP rs141164659, ExAC rs141164659, TOPMed rs141164659, gnomAD rs141164659, REVEL 0.03, CADD 11.00
- L3del (p.Leu3del), rs765087525, gnomAD 21-33241925-GCTT-, CADD 8.57
- S4G (p.Ser4Gly), Ensembl rs111986902
- S4P (p.Ser4Pro), gnomAD 21-33241930-TGA-T, CADD 22.60
- S4S (p.Ser4Ser), gnomAD 21-33241934-C-T, CADD 9.61
- Q5R (p.Gln5Arg), rs762005656, ClinGen CA10005494, ClinVar RCV002766391, ExAC rs762005656, REVEL 0.02, CADD 1.32, Uncertain significance, not provided
- Q5K (p.Gln5Lys), gnomAD 21-33241896-C-A, CADD 14.60
- Q5* (p.Gln5Ter), rs1376591604, gnomAD 21-33241896-C-T, CADD 15.70
- Q5Q (p.Gln5Gln), rs369214329, gnomAD 21-33241898-A-G, CADD 15.70
- Q5L (p.Gln5Leu), rs775090074, gnomAD 21-33241932-AGCCA, CADD 22.50
- N6S (p.Asn6Ser), TOPMed rs1986964409, REVEL 0.03, CADD 3.48
- A7T (p.Ala7Thr), gnomAD rs1331375284, REVEL 0.04, CADD 7.36
- A7G (p.Ala7Gly), rs772755254, gnomAD 21-33241918-C-G, CADD 9.94
- A7E (p.Ala7Glu), gnomAD 21-33241918-C-A, CADD 9.83
- A7A (p.Ala7Ala), rs925932774, gnomAD 21-33241919-A-G, CADD 10.80
- F8S (p.Phe8Ser), rs2229207, ClinGen CA118670, cosmic curated COSV59747, ClinVar RCV000007711, REVEL 0.01, CADD 1.04, Benign, Immunodeficiency 45; not specified; not provided
- F8V (p.Phe8Val), gnomAD rs1451529794, REVEL 0.03, CADD 4.41
- F8Y (p.Phe8Tyr), 1000Genomes rs2229207, ESP rs2229207, ExAC rs2229207, TOPMed rs2229207, Benign
- F8L (p.Phe8Leu), gnomAD 21-33241944-T-C, REVEL 0.05, CADD 6.46
- F8I (p.Phe8Ile), gnomAD 21-33241944-T-A, REVEL 0.03, CADD 5.75
- F8F (p.Phe8Phe), rs1384407817, gnomAD 21-33241946-C-T, CADD 0.53
- I9M (p.Ile9Met), rs750264158, ClinGen CA10005495, ClinVar RCV001982607, ClinVar RCV004043698, REVEL 0.06, CADD 1.42, Uncertain significance, not provided; not specified
- I9R (p.Ile9Arg), rs771202405, gnomAD 21-33230533-T-G, CADD 8.48
- I9K (p.Ile9Lys), rs771202405, gnomAD 21-33230533-T-A, CADD 8.33
- I9V (p.Ile9Val), rs1021194427, gnomAD 21-33230556-A-G, CADD 7.76
- I9I (p.Ile9Ile), rs750264158, gnomAD 21-33241949-C-T, CADD 5.39
- F10C (p.Phe10Cys), TOPMed rs1340060960, gnomAD rs1340060960, REVEL 0.05, CADD 17.40
- F10I (p.Phe10Ile), rs1051393, ClinGen CA10005497, ClinVar RCV003397212, 1000Genomes rs1051393, REVEL 0.01, CADD 0.00, Uncertain significance, Associated with severe COVID-19 disease
- F10L (p.Phe10Leu), 1000Genomes rs1051393, ESP rs1051393, ExAC rs1051393, TOPMed rs1051393, Benign
- F10V (p.Phe10Val), rs1051393, ClinGen CA10005496, cosmic curated COSV59747, ClinVar RCV001523494, REVEL 0.01, CADD 0.00, Benign, Immunodeficiency 45; not provided; not specified
- R11G (p.Arg11Gly), ExAC rs530997490, TOPMed rs530997490, gnomAD rs530997490, REVEL 0.03, CADD 4.71
- R11S (p.Arg11Ser), rs2516693891, ClinGen CA410093781, ClinVar RCV002303644, Uncertain significance, not provided
- R11T (p.Arg11Thr), 1000Genomes rs554510864, ExAC rs554510864, TOPMed rs554510864, gnomAD rs554510864, REVEL 0.13, CADD 11.90, Uncertain significance, not specified
- S12L (p.Ser12Leu), Ensembl rs2123467830
- S12T (p.Ser12Thr), TOPMed rs1198227916
- S12N (p.Ser12Asn), gnomAD 21-33241894-G-A, CADD 15.90
- S12R (p.Ser12Arg), gnomAD 21-33241895-T-A, CADD 15.40
- S12P (p.Ser12Pro), gnomAD 21-33241956-T-C, REVEL 0.10, CADD 4.60
- S12S (p.Ser12Ser), rs780623117, gnomAD 21-33241958-A-G, CADD 0.12
- L13F (p.Leu13Phe), ExAC rs752249011, gnomAD rs752249011, REVEL 0.17, CADD 9.57, Uncertain significance, not specified
- L13L (p.Leu13Leu), rs1243904936, gnomAD 21-33241961-T-G, CADD 0.18
- N14H (p.Asn14His), TOPMed rs1227667824, gnomAD rs1227667824, REVEL 0.11, CADD 1.13
- L15F (p.Leu15Phe), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- L15W (p.Leu15Trp), rs755873190, ClinGen CA10005502, ClinVar RCV001926646, ClinVar RCV004927759, REVEL 0.49, CADD 17.30, Uncertain significance, not specified; not provided
- V16F (p.Val16Phe), gnomAD rs1040634145, REVEL 0.13, CADD 0.70
- V16I (p.Val16Ile), gnomAD rs1040634145, REVEL 0.09, CADD 0.33
- L17I (p.Leu17Ile), NCI-TCGA TCGA novel, REVEL 0.32, CADD 17.70, Variant assessed as somatic; moderate impact.
- L17F (p.Leu17Phe), gnomAD 21-33241971-C-T, REVEL 0.36, CADD 19.40
- L17L (p.Leu17Leu), gnomAD 21-33241973-C-T, CADD 6.10
- M18L (p.Met18Leu), ExAC rs777547168, gnomAD rs777547168, REVEL 0.09, CADD 0.07
- M18T (p.Met18Thr), rs1476050885, ClinGen CA410093900, ClinVar RCV002829852, TOPMed rs1476050885, REVEL 0.06, CADD 14.60, Uncertain significance, not provided
- M18V (p.Met18Val), gnomAD 21-33241974-A-G, REVEL 0.09, CADD 0.01
- V19A (p.Val19Ala), gnomAD rs1286009698, REVEL 0.54, CADD 19.80
- V19L (p.Val19Leu), gnomAD rs1170127205, REVEL 0.48, CADD 33.00
- V19V (p.Val19Val), gnomAD 21-33243674-G-A, CADD 12.10
- Y20C (p.Tyr20Cys), rs781731891, ClinGen CA10005527, ClinVar RCV002591341, ExAC rs781731891, REVEL 0.08, CADD 0.01, Uncertain significance, not provided
- Y20H (p.Tyr20His), TOPMed rs1354910199, gnomAD rs1354910199, REVEL 0.06, CADD 4.33
- Y20N (p.Tyr20Asn), gnomAD 21-33243675-T-A, REVEL 0.14, CADD 8.28
- I21V (p.Ile21Val), TOPMed rs1987169015, REVEL 0.06, CADD 0.20
- I21M (p.Ile21Met), rs1221356759, gnomAD 21-33241916-A-G, CADD 10.90
- S22I (p.Ser22Ile), rs143742626, ClinGen CA10005528, ClinVar RCV001946538, ClinVar RCV004042978, REVEL 0.36, CADD 15.60, Uncertain significance, not specified; not provided
- S22N (p.Ser22Asn), gnomAD 21-33243682-G-A, REVEL 0.33, CADD 18.00
- S22S (p.Ser22Ser), rs769867496, gnomAD 21-33243683-C-T, CADD 9.47
- L23I (p.Leu23Ile), ExAC rs773217322, gnomAD rs773217322, REVEL 0.19, CADD 20.80
- L23F (p.Leu23Phe), gnomAD 21-33243684-C-T, REVEL 0.12, CADD 16.60
- L23L (p.Leu23Leu), rs200546356, gnomAD 21-33243686-C-T, CADD 2.68
- V24M (p.Val24Met), rs561488102, ClinGen CA10005532, cosmic curated COSV59750, ClinVar RCV001884860, REVEL 0.10, CADD 0.07, Uncertain significance, not provided; not specified
- V24L (p.Val24Leu), gnomAD 21-33243687-G-T, REVEL 0.10, CADD 0.06
- F25L (p.Phe25Leu), ExAC rs774056629, TOPMed rs774056629, gnomAD rs774056629, REVEL 0.07, CADD 4.58
- G26A (p.Gly26Ala), TOPMed rs1179133357, gnomAD rs1179133357, REVEL 0.17, CADD 3.54
- G26S (p.Gly26Ser), gnomAD 21-33230538-G-A, CADD 9.03
- G26G (p.Gly26Gly), rs562283425, gnomAD 21-33230540-C-T, CADD 10.10
- G26D (p.Gly26Asp), gnomAD 21-33243694-G-A, REVEL 0.28, CADD 3.81
- I27T (p.Ile27Thr), TOPMed rs1987172547, REVEL 0.05, CADD 6.34
- S28L (p.Ser28Leu), gnomAD rs1490350098, REVEL 0.08, CADD 14.90
- S28S (p.Ser28Ser), rs978334718, gnomAD 21-33243701-A-G, CADD 2.21
- Y29H (p.Tyr29His), Ensembl rs2123474578
- Y29C (p.Tyr29Cys), gnomAD 21-33243703-A-G, REVEL 0.05, CADD 0.02
- Y29Y (p.Tyr29Tyr), rs1200769826, gnomAD 21-33243704-T-C, CADD 0.21
- D30E (p.Asp30Glu), rs765337440, ClinGen CA10005534, ClinVar RCV001942364, ExAC rs765337440, REVEL 0.06, CADD 1.24, Uncertain significance, not provided
- D30G (p.Asp30Gly), gnomAD 21-33243706-A-G, REVEL 0.05, CADD 1.01
- D30V (p.Asp30Val), gnomAD 21-33243706-A-T, REVEL 0.03, CADD 3.44
- S31L (p.Ser31Leu), cosmic curated COSV59751, ExAC rs767168940, TOPMed rs767168940, gnomAD rs767168940, REVEL 0.07, CADD 0.23, Likely benign, not specified
- S31W (p.Ser31Trp), rs767168940, ClinGen CA410094795, ClinVar RCV001956643, ExAC rs767168940, REVEL 0.11, CADD 0.39, Uncertain significance, not provided
- S31S (p.Ser31Ser), rs775529446, gnomAD 21-33243710-G-A, CADD 1.57
- P32A (p.Pro32Ala), TOPMed rs1463037104
- P32T (p.Pro32Thr), gnomAD 21-33230526-C-A, CADD 8.77
- P32L (p.Pro32Leu), rs1985973656, gnomAD 21-33230527-C-T, CADD 5.08
- P32P (p.Pro32Pro), gnomAD 21-33230528-C-A, CADD 1.76
- P32S (p.Pro32Ser), rs1422711410, gnomAD 21-33230535-C-T, CADD 9.88
- P32R (p.Pro32Arg), rs896669663, gnomAD 21-33230536-C-G, CADD 9.43
- P32Q (p.Pro32Gln), gnomAD 21-33230536-C-A, CADD 9.26
- D33G (p.Asp33Gly), Ensembl rs1039974300, REVEL 0.14, CADD 11.90
- D33D (p.Asp33Asp), rs1987277966, gnomAD 21-33244952-T-C, CADD 0.49
- Y34C (p.Tyr34Cys), NCI-TCGA TCGA novel, TOPMed rs1987278249, gnomAD rs1987278249, REVEL 0.09, CADD 5.63, Uncertain significance, not specified
- Y34Y (p.Tyr34Tyr), rs764608665, gnomAD 21-33244955-C-T, CADD 0.12
- Y34* (p.Tyr34Ter), gnomAD 21-33244955-C-A, CADD 24.80
- T35A (p.Thr35Ala), ExAC rs750091350, TOPMed rs750091350, REVEL 0.00, CADD 0.00
- T35S (p.Thr35Ser), ExAC rs750091350, TOPMed rs750091350, REVEL 0.00, CADD 0.00
- T35P (p.Thr35Pro), gnomAD 21-33241905-A-C, CADD 9.16
- T35I (p.Thr35Ile), rs1360952096, gnomAD 21-33241906-C-T, CADD 7.34
- T35R (p.Thr35Arg), gnomAD 21-33244953-TAC-T, CADD 7.56
- T35T (p.Thr35Thr), rs1399907886, gnomAD 21-33244958-A-G, CADD 1.45
- D36G (p.Asp36Gly), gnomAD 21-33244960-A-G, REVEL 0.07, CADD 2.31
- D36D (p.Asp36Asp), rs1306309401, gnomAD 21-33244961-T-C, CADD 0.28
- D36E (p.Asp36Glu), gnomAD 21-33244961-T-A, REVEL 0.06, CADD 0.15
- E37Q (p.Glu37Gln), rs201003373, ClinGen CA10005561, ClinVar RCV001977676, UniProt VAR 084099, REVEL 0.06, CADD 5.89, Uncertain significance, not provided
- E37D (p.Glu37Asp), gnomAD 21-33241896-CAAGA, CADD 13.20
- E37* (p.Glu37Ter), gnomAD 21-33241899-G-T, CADD 8.17
- E37K (p.Glu37Lys), rs754477131, gnomAD 21-33241899-G-A, CADD 7.03
- E37G (p.Glu37Gly), rs780685026, gnomAD 21-33241900-A-G, CADD 11.00
- E37E (p.Glu37Glu), rs1986956181, gnomAD 21-33241901-G-A, CADD 11.90
- S38C (p.Ser38Cys), ExAC rs767982536, TOPMed rs767982536, gnomAD rs767982536, REVEL 0.09, CADD 14.40
- C39* (p.Cys39Ter), rs1164631131, ClinGen CA410095465, ClinVar RCV002040769, TOPMed rs1164631131, CADD 34.00, Pathogenic
- C39F (p.Cys39Phe), gnomAD 21-33230541-A-ATT, CADD 4.71
- C39Y (p.Cys39Tyr), gnomAD 21-33230545-G-A, CADD 9.60
- C39C (p.Cys39Cys), rs1470625488, gnomAD 21-33230546-C-T, CADD 6.54
- C39S (p.Cys39Ser), rs1347976890, gnomAD 21-33230550-T-A, CADD 8.60
- T40A (p.Thr40Ala), TOPMed rs1987281579
- T40I (p.Thr40Ile), TOPMed rs1987281854
- T40S (p.Thr40Ser), gnomAD 21-33244972-C-G, REVEL 0.18, CADD 0.01
- F41S (p.Phe41Ser), rs149204840, ClinGen CA10005563, ClinVar RCV002593953, ClinVar RCV004065604, REVEL 0.36, CADD 22.30, Uncertain significance, not provided; not specified
- F41C (p.Phe41Cys), gnomAD 21-33244975-T-G, REVEL 0.31, CADD 22.40
- F41F (p.Phe41Phe), gnomAD 21-33244976-C-T, CADD 0.13
- F41L (p.Phe41Leu), gnomAD 21-33244976-C-A, REVEL 0.14, CADD 0.00
- K42E (p.Lys42Glu), ExAC rs756652516, TOPMed rs756652516, gnomAD rs756652516, REVEL 0.34, CADD 17.10, Uncertain significance, not specified
- K42N (p.Lys42Asn), TOPMed rs9754221, gnomAD rs9754221, NCI-TCGA Cosmic COSV5974, cosmic curated COSV59747, Variant assessed as somatic; moderate impact.
- K42R (p.Lys42Arg), gnomAD 21-33241891-A-G, CADD 16.00
- K42Q (p.Lys42Gln), gnomAD 21-33241920-A-C, CADD 16.40
- K42T (p.Lys42Thr), gnomAD 21-33241921-A-C, CADD 14.70
- K42M (p.Lys42Met), gnomAD 21-33241921-A-T, CADD 14.70
- K42K (p.Lys42Lys), gnomAD 21-33241922-G-A, CADD 15.90
- I43L (p.Ile43Leu), rs754395606, ClinGen CA10005565, ClinVar RCV001957757, ClinVar RCV004043021, REVEL 0.15, CADD 0.45, Uncertain significance, not specified; not provided
- I43M (p.Ile43Met), ExAC rs749748756, REVEL 0.10, CADD 0.31
- I43T (p.Ile43Thr), rs2516705053, ClinGen CA410095510, ClinVar RCV002872458, REVEL 0.44, CADD 22.50, Uncertain significance, not provided
- I43V (p.Ile43Val), ExAC rs754395606, TOPMed rs754395606, gnomAD rs754395606, Uncertain significance
- I43R (p.Ile43Arg), rs1422057210, gnomAD 21-33244977-A-AAG, CADD 19.20
- S44del (p.Ser44del), gnomAD 21-33244981-TATC-, CADD 5.91
- S44P (p.Ser44Pro), gnomAD 21-33244983-T-C, REVEL 0.38, CADD 14.30
- S44* (p.Ser44Ter), gnomAD 21-33244984-C-A, CADD 33.00
- S44S (p.Ser44Ser), rs1601799494, gnomAD 21-33244985-A-G, CADD 1.47
- L45S (p.Leu45Ser), TOPMed rs1461393554, gnomAD rs1461393554, REVEL 0.15, CADD 20.90
- R46* (p.Arg46Ter), rs778657924, ClinGen CA10005567, ClinVar RCV002635186, ExAC rs778657924, CADD 34.00, Pathogenic
- R46Q (p.Arg46Gln), rs778792208, NCI-TCGA Cosmic COSV5974, cosmic curated COSV59746, ExAC rs778792208, REVEL 0.31, CADD 14.80, Variant assessed as somatic; moderate impact.
- R46R (p.Arg46Arg), gnomAD 21-33244989-C-A, CADD 7.42
- R46L (p.Arg46Leu), gnomAD 21-33244990-G-T, REVEL 0.29, CADD 20.30
- N47S (p.Asn47Ser), TOPMed rs1987285488
- N47T (p.Asn47Thr), gnomAD 21-33244993-A-C, REVEL 0.40, CADD 22.70
- F48S (p.Phe48Ser), gnomAD rs1427913818, REVEL 0.52, CADD 22.60
- R49Q (p.Arg49Gln), rs533026439, ClinGen CA10005570, cosmic curated COSV59749, ClinVar RCV001921515, REVEL 0.08, CADD 14.30, Uncertain significance, not provided
- R49W (p.Arg49Trp), rs375487848, cosmic curated COSV10057, ESP rs375487848, ExAC rs375487848, REVEL 0.46, CADD 25.60, Variant assessed as somatic; moderate impact.
- R49R (p.Arg49Arg), rs1987286608, gnomAD 21-33245000-G-A, CADD 8.38
- S50F (p.Ser50Phe), rs1217206327, NCI-TCGA Cosmic COSV1005, cosmic curated COSV10057, TOPMed rs1217206327, REVEL 0.20, CADD 16.70, Variant assessed as somatic; moderate impact.
- S50Y (p.Ser50Tyr), gnomAD 21-33245002-C-A, REVEL 0.28, CADD 19.60
- S50S (p.Ser50Ser), gnomAD 21-33245003-C-A, CADD 1.84
- S53P (p.Ser53Pro), rs1987287426, ClinGen CA410095635, ClinVar RCV001813168, ClinVar RCV002284216, REVEL 0.53, CADD 23.90, Conflicting interpretations, not provided; Immunodeficiency 45
- S53del (p.Ser53del), rs1468003457, gnomAD 21-33245008-TATC-, CADD 13.70
- S53H (p.Ser53His), rs1334998917, gnomAD 21-33245009-AT-A, CADD 23.50
- S53* (p.Ser53Ter), gnomAD 21-33245011-C-A, CADD 35.00
- S53S (p.Ser53Ser), gnomAD 21-33245012-A-T, CADD 1.20
- W54* (p.Trp54Ter), NCI-TCGA Cosmic COSV1005, NCI-TCGA Cosmic COSV5975, cosmic curated COSV59750, CADD 37.00, Variant assessed as somatic; high impact.
- W54C (p.Trp54Cys), NCI-TCGA Cosmic COSV1005, cosmic curated COSV10057, NCI-TCGA Cosmic COSV5975, Variant assessed as somatic; moderate impact.
- E55D (p.Glu55Asp), gnomAD rs1453614680, REVEL 0.27, CADD 21.50
- E55* (p.Glu55Ter), gnomAD 21-33245016-G-T, CADD 38.00
- E55K (p.Glu55Lys), gnomAD 21-33245016-G-A, REVEL 0.21, CADD 19.30
- E55E (p.Glu55Glu), gnomAD 21-33245018-A-G, CADD 6.76
- L56L (p.Leu56Leu), rs36088527, gnomAD 21-33245019-T-C, CADD 9.57
- K57R (p.Lys57Arg), TOPMed rs1359940308, gnomAD rs1359940308, REVEL 0.35, CADD 22.00
- K57del (p.Lys57del), gnomAD 21-33245020-TAAA-, CADD 12.30
- N58S (p.Asn58Ser), Ensembl rs2123478412
- N58T (p.Asn58Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- N58K (p.Asn58Lys), gnomAD 21-33245020-T-TA, CADD 24.80
- N58H (p.Asn58His), gnomAD 21-33245025-A-C, REVEL 0.34, CADD 21.80
- H59Q (p.His59Gln), gnomAD rs1323903015, REVEL 0.11, CADD 3.90
- H59Y (p.His59Tyr), rs768519080, ClinGen CA10005573, cosmic curated COSV59749, ClinVar RCV001302296, REVEL 0.24, CADD 12.70, Uncertain significance, not provided
- H59R (p.His59Arg), rs1347064019, gnomAD 21-33230548-A-G, CADD 10.20
Public IFNAR2 analysis runs
- IFNAR2 analysis run — IFNAR2 (720 variants) — completed 2026-08-22